Firm that developed cancer breath test awarded £36m

Firm that developed cancer breath test awarded £36m

Owlstone Medical, a company that has developed an early diagnostics device for cancer, has been awarded a research prize of up to £36.5m.

Owlstone Medical gets up to US$49.1M to develop multi-cancer breath tests

British medtech operator Owlstone Medical has been awarded a hefty sum to propel development of at-home multi-cancer breath and urine tests.

British Owlstone Medical wins ARPA-H award, but will it materialize? - European Biotechnology Magazine

Owlstone Medical, a pioneer in breath-based diagnostics from Cambridge (UK), has been awarded up to US$49.1m by the U.S. health innovation agency ARPA-H under its POSEIDON programme. The funding backs development of a synthetic-sensor MCED test capable of detecting over 30 solid tumours at Stage I using breath and urine samples, intended for at-home, over-the-counter use. But will ARPA-H be committed to funding if the restructuring of NIH and HH…